[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360026-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360026-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mbd2-suppresses-sfrp1-expression-and-promotes-colorectal-cancer-development-by-blocking-med19-binding-to-its-methylated-promoter","MBD2 suppresses SFRP1 expression and promotes colorectal cancer development by blocking MED19 binding to its methylated promoter","","DNA methylation contributes to colorectal cancer (CRC) through silencing tumor suppressor genes such as SFRP1, often via promoter hypermethylation. This study examines MBD2, a DNA methylation reader, and clarifies how methylation suppresses gene expression without changing methylation status at the SFRP1 promoter. CRC models with MBD2 knockdown or the inhibitor KCC07 show increased SFRP1, decreased β-catenin and Wnt activity, reduced proliferation, enhanced apoptosis, and suppressed tumor growth in vivo, mediated by disrupted MED19 binding, reduced RNA polymerase II CTD-S7 phosphorylation, and impaired transcription.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mbd2-suppresses-sfrp1-expression-and-promotes-colorectal-cancer-development-by-blocking-med19-binding-to-its-methylated-promoter/360026/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mbd2-suppresses-sfrp1-expression-and-promotes-colorectal-cancer-development-by-blocking-med19-binding-to-its-methylated-promoter/360026.png","ImageObject",300,407,{"name":42,"@type":43},"Bintang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does MBD2 play in SFRP1 silencing in colorectal cancer?","Question",{"text":63,"@type":64},"MBD2 contributes to SFRP1 epigenetic silencing. The study shows that blocking MED19 binding to the methylated SFRP1 promoter reduces transcriptional activity and increases SFRP1 expression when MBD2 is inhibited.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was MBD2 inhibited in the colorectal cancer models?",{"text":68,"@type":64},"MBD2 was inhibited using siRNA or the small molecule inhibitor KCC07. Effects were evaluated on SFRP1 and β-catenin expression, Wnt pathway activity, cell proliferation, apoptosis, and tumor growth in vivo.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic outcome did KCC07 produce in colorectal cancer?",{"text":72,"@type":64},"KCC07 upregulated SFRP1, downregulated β-catenin, suppressed Wnt signaling, inhibited CRC cell proliferation, promoted apoptosis, and suppressed tumor growth in vivo.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360026,1790679186,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","CANCER BIOLOGY & THERAPY 2026, VOL. 27, NO. 1, 2667568  \n[https://doi.org/10.1080/15384047.2026.2667568](https://doi.org/10.1080/15384047.2026.2667568)  \nRESEARCH ARTICLE     \nMBD2 suppresses SFRP1 expression and promotes colorectal cancer development by blocking MED19 binding to its methylated promoter  \nXiuji Huanga, 1 , Tingting Luob, 1, Lingling Keb, 1, Shaoting Guanb, Huixian Wub, Bo Lib, Yuting Liub and Jian Qib   \naDepartment of Respiratory and Critical Care Medicine, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China; bDigestive Diseases Center, Guangdong Provincial Key Laboratory of Digestive Cancer Research, Guangdong-Hong Kong-Macau University Joint Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China  \nABSTRACT  \nBackground: The Wnt signaling pathway antagonist SFRP1 is frequently silenced by promoter DNA hypermethylation in colorectal cancer (CRC) . MBD2, a DNA methylation reader, is known to contribute to SFRP1 epigenetic silencing. Previous work showed that MBD2 critically suppresses SFRP1 expression without altering promoter methylation, though the underlying mechanism remained unclear. Elucidating how DNA methylation silences tumor suppressor genes, such as SFRP1, could reveal novel therapeutic targets with significant clinical potential.  \nMethods: MBD2 was inhibited in CRC models using either siRNA or a small molecule inhibitor (KCC07) . The effects on SFRP1 and β-catenin expression, Wnt pathway activity, cell proliferation, and apoptosis were assessed. Tumor growth was also evaluated in vivo. Mechanistic studies investigated the role of MBD2 in mediating MED19 binding to the SFRP1 promoter and its impact on RNA polymerase II CTD-S7 phosphorylation. Results: The IC50 of KCC07 was 23.25 μM in SW480 cells, 26.83 μM in HCT116 cells, and 39.66 μM in NCM460 cells. Inhibition of MBD2, either genetically or pharmacologically with KCC07, upregulated SFRP1 expression, downregulated β-catenin, and suppressed the Wnt pathway. KCC07 treatment also inhibited CRC cell proliferation, promoted apoptosis, and suppressed tumor growth in vivo. Mechanistically, MBD2 was found to silence SFRP1 by blocking MED19 binding to its promoter, which subsequently reduced RNA polymerase II CTD-S7 phosphorylation and impaired transcription.  \nConclusions: This study reveals a novel mechanism whereby DNA methylation suppresses gene expression via MBD2, independent of changes in methylation status, by disrupting MED19 binding and subsequent transcription. Targeting MBD2 represents a promising therapeutic strategy for colorectal cancer.  \nARTICLE HISTORY  \nReceived 28 January 2026 Revised 26 April 2026 Accepted 27 April 2026  \nKEYWORDS  \nDNA methylation; MBD2; MED19; SFRP1; Colorectal cancer  \nIntroduction  \nColorectal cancer (CRC) ranks as the third most common malignancy and the second leading cause of cancer-related mortality worldwide, with over 1.9 million new cases and approximately 900,000 deaths annually. 1 Despite therapeutic advances, CRC demonstrates limited sensitivity to conventional treatments, resulting in unsatisfactory survival rates.2-4 Therefore, identifying novel therapeutic targets remains a critical need.  \nDNA methylation plays a pivotal role in gene expression regulation.5 Neoplastic cells exhibit distinct methylation patterns, featuring genome-wide hypomethylation coupled with localized CpG island hypermethylation.6,7 These epigenetic alterations significantly contribute to CRC pathogenesis, with tumor suppressor gene silencing via promoter hypermethylation serving as a key driver of oncogenesis.8,9  \nCONTACT Yuting Liu  [liuyuting@sysush.com](liuyuting@sysush.com); Jian Qi, MD  qijian7@mail.sysu.edu.cn  Digestive Diseases Center, Guangdong Provincial Key Laboratory of Digestive Cancer Research, Guangdong-Hong Kong-Macau University Joint Laboratory of Digestive Cancer Research, The S1eventh Affiliated Hospital of","cbCaifag9MMl6SiH","https://ap.wps.com/l/cbCaifag9MMl6SiH","pdf",5575587,"English","# Abstract\n# Methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What role does MBD2 play in SFRP1 silencing in colorectal cancer?\",\"answer\":\"MBD2 contributes to SFRP1 epigenetic silencing. The study shows that blocking MED19 binding to the methylated SFRP1 promoter reduces transcriptional activity and increases SFRP1 expression when MBD2 is inhibited.\"},{\"question\":\"How was MBD2 inhibited in the colorectal cancer models?\",\"answer\":\"MBD2 was inhibited using siRNA or the small molecule inhibitor KCC07. Effects were evaluated on SFRP1 and β-catenin expression, Wnt pathway activity, cell proliferation, apoptosis, and tumor growth in vivo.\"},{\"question\":\"What therapeutic outcome did KCC07 produce in colorectal cancer?\",\"answer\":\"KCC07 upregulated SFRP1, downregulated β-catenin, suppressed Wnt signaling, inhibited CRC cell proliferation, promoted apoptosis, and suppressed tumor growth in vivo.\"}]","MBD2 suppresses SFRP1 expression and promotes colorectal cancer development by blocking MED19 binding to its methylated promoter | PDF",1790138534,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e0eb6ba33418d9f23a90c662841fe8e.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a5e01e84fcb3ab1f15982e83fd9220f.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ddacb2646b5effa7032edc99d6de860.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ff62d8c806a8f2424ea249f8d351a34.webp",980,1306]